Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Parkhurst Website

Maria R. Parkhurst, Ph.D.

Selected Publications

1)  Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.
A Novel Murine T-Cell Receptor Targeting NY-ESO-1.
J. Immunother. 37: 135-46, 2014.
2)  Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME.
Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.
J Transl Med. 10: 69, 2012.
3)  Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA.
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2011.
4)  Tran E, Turcotte S, Gros A, Robbins PF, Lu Y, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science. 344: 641-5, 2014.
5)  Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA.
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
J. Immunol. 186: 685-96, 2011.
6)  Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA.
Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a.
Hum. Gene Ther. 22: 107-15, 2011.
7)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011.
8)  Parkhurst M, Rosenberg S.
No evidence for presentation of hTERT:865-873 on tumor cells.
Blood. e-letter: August 18, 2010.
Full Text Article. [Journal]
9)  Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA.
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Clin. Cancer Res. 15: 169-80, 2009.
10)  Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA.
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer Res. 67: 2425-9, 2007.
11)  Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR.
Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
J. Immunother. 29: 616-27, 2006.
12)  Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA.
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Clin. Cancer Res. 10: 4688-98, 2004.
13)  Parkhurst MR, Riley JP, Robbins PF, Rosenberg SA.
Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
J. Immunother. 27: 79-91, 2004.
14)  Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, Shu S.
Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.
Dev Biol. 116: 169-78; discussion 179-86, 2004.
15)  Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S.
Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
J. Immunol. 170: 5317-25, 2003.
16)  Riley JP, Rosenberg SA, Parkhurst MR.
Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
J. Immunol. Methods. 276: 103-19, 2003.
17)  Rosenberg SA, Tong-On P, Li Y, Riley JP, El-Gamil M, Parkhurst MR, Robbins PF.
Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.
J. Immunol. 168: 2402-7, 2002.
18)  Riley JP, Rosenberg SA, Parkhurst MR.
Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
J. Immunother. 24: 212-20, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/2/2014.